Which Drug Makers Boosted R&D Spending the Most?


Published On: August 29th, 2009

Overall, corporate America cut R&D spending in the first half of this year — no surprise, given the tenor of the times. But some companies bucked the trend.

BusinessWeek is out with a list of 25 companies that aggressively increased R&D spending, and drug makers snagged the top spots.

Merck was number one on the list, boosting its R&D spending by more than $370 million. But much of that spending wasn’t the traditional pharma R&D work of paying its own scientists to discover and develop new drugs; instead, it was licensing payments to small biotech shops and the like for rights to promising experimental compounds.

Biogen Idec, Eli Lilly, Bristol-Myers Squibb and Gilead rounded out the top five, for varying reasons. Lilly folded in ImClone after last year’s big acquisition; Gilead has more drugs in late-stage trials, which include lots of patients and are very expensive to run.

Image: iStockphoto

Continued here: 
Which Drug Makers Boosted R&D Spending the Most?



Loading...


Comments are closed.